AAD 2023

New Developments in Dermatology

Atopic Dermatitis: State of the Art

As-needed ruxolitinib shows successful long-term symptom control in AD

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, TRuE-AD1 and TRuE-AD2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:43

Dupilumab: a viable option for atopic hand and foot eczema

Presented By

Prof. Eric Simpson, Oregon Health & Science University, OR, USA

Trial

Phase 3, LIBERTY-AD-HAFT

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:33

Topical roflumilast beneficial in atopic dermatitis

Presented By

Prof. Lawrence Eichenfield, University of California San Diego, CA, USA

Trial

Phase 3, INTEGUMENT-1 and INTEGUMENT-2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:27

IL-22 receptor blocker reduces itch and skin lesions in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:17

Psoriasis: New Developments

Hidradenitis Suppurativa: What You Need to Know

Pearls of the Posters

Biologics in psoriasis: can they prevent joint involvement?

Presented By

Ms Kathleen Miao, Keck School of Medicine of USC, CA, USA

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:46

JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata

Presented By

Dr Maryanne Senna, Lahey Hospital and Medical Center, MA, USA

Trial

Phase 3, THRIVE-AA1

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:41

Biomarkers predicting response of different CSU treatments in children

Presented By

Mr Alex Nguyen, McGill University, Canada

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:35